Real-world data for heart failure: Closing evidence gaps across the patient journey
The evolution of heart failure treatment and research Heart failure remains one of the most...
Turning claims into interoperable evidence More means more. In a world where anyone can make claims, only taXonomy Pathways makes claims interoperable. That’s the difference between simply collecting data and creating evidence that is complete,...
The evolution of heart failure treatment and research Heart failure remains one of the most...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
At HealthVerity, community is at the heart of who we are. Each year, our team members come together...
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
The evolution of heart failure treatment and research Heart failure remains one of the most prevalent and costly chronic diseases in the United States, affecting more than 6.7 million adults and projected to reach 8.7 million by 2030.1 It is the lead...